FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4296430500> ?p ?o ?g. }

• W4296430500 abstract "<h3></h3> Children with progressive familial intrahepatic cholestasis (PFIC) who received odevixibat in the 24-week PEDFIC 1 study had significant reductions in total serum bile acids (sBAs) vs placebo-treated patients. Odevixibat was approved in 2021 in the European Union for treatment of PFIC in patients ≥6 months old. Here, we evaluated the effect of concomitant ursodeoxycholic acid (UDCA) on sBA concentrations in odevixibat-treated patients from PEDFIC 1 (n=42) who met sBA response (R) criteria or not; we also assessed whether excluding UDCA concentrations from total sBAs altered the proportion of patients with sBA R. Patients eligible for PEDFIC 1 had elevated sBAs at screening. Concomitant UDCA was allowed provided the patient’s dose was stable. The threshold for sBA R was sBAs ≤70 μmol/L or sBAs reduced ≥70% from baseline (BL). The PEDFIC 1 per-protocol definition of sBA R was based on average measurements taken at weeks 22 and 24; those not meeting this criteria, including early-exit patients, were considered nonresponders (NRs). Using this per-protocol definition, rates of sBA R excluding the contribution of UDCA were also analysed. Finally, the proportion of patients who met sBA R was re-evaluated to include the last available sBA assessment for early-exit patients. sBA concentration and composition (ie, total, primary, and secondary sBAs, including UDCA) were evaluated at BL and at the end of treatment (EOT). Secondary sBA concentrations (and therefore, total sBAs) were evaluated with and without UDCA concentration included. In the primary analysis of PEDFIC 1 study data, 14/42 patients met criteria for sBA R at EOT. When using the same per-protocol definition but excluding UDCA concentrations, 13/42 of patients met sBA R criteria. Using an updated R definition, 17/42 patients had an sBA R (3 early-exit patients were now counted as having an sBA R). Median concentrations of total and primary sBAs decreased considerably from BL to EOT in these Rs both with and without UDCA; these parameters remained largely unchanged in NRs regardless of whether UDCA concentration was considered (table 1). In all odevixibat-treated patients regardless of sBA R status, median values for secondary sBAs without UDCA at BL and at EOT were near 0 (table 1). The proportion of patients with sBA R to odevixibat in PEDFIC 1 did not change appreciably when serum UDCA concentrations were excluded from total sBA levels. In patients with sBA R per an updated definition, large reductions in sBAs occurred whether or not UDCA concentration was included." @default.
• W4296430500 created "2022-09-20" @default.
• W4296430500 creator A5000708233 @default.
• W4296430500 creator A5031718124 @default.
• W4296430500 creator A5032174537 @default.
• W4296430500 creator A5083405368 @default.
• W4296430500 date "2022-09-01" @default.
• W4296430500 modified "2023-10-17" @default.
• W4296430500 title "P61 Total, primary, and secondary serum bile acid concentrations in patients with progressive familial intrahepatic cholestasis with serum bile acid response or not with odevixibat treatment: assessing the contribution of ursodeoxycholic acid concentration" @default.
• W4296430500 doi "https://doi.org/10.1136/gutjnl-2022-basl.112" @default.
• W4296430500 hasPublicationYear "2022" @default.
• W4296430500 type Work @default.
• W4296430500 citedByCount "0" @default.
• W4296430500 crossrefType "proceedings-article" @default.
• W4296430500 hasAuthorship W4296430500A5000708233 @default.
• W4296430500 hasAuthorship W4296430500A5031718124 @default.
• W4296430500 hasAuthorship W4296430500A5032174537 @default.
• W4296430500 hasAuthorship W4296430500A5083405368 @default.
• W4296430500 hasConcept C126322002 @default.
• W4296430500 hasConcept C142724271 @default.
• W4296430500 hasConcept C204787440 @default.
• W4296430500 hasConcept C27081682 @default.
• W4296430500 hasConcept C2778593092 @default.
• W4296430500 hasConcept C2779384505 @default.
• W4296430500 hasConcept C2779399885 @default.
• W4296430500 hasConcept C2780965833 @default.
• W4296430500 hasConcept C71924100 @default.
• W4296430500 hasConcept C90924648 @default.
• W4296430500 hasConceptScore W4296430500C126322002 @default.
• W4296430500 hasConceptScore W4296430500C142724271 @default.
• W4296430500 hasConceptScore W4296430500C204787440 @default.
• W4296430500 hasConceptScore W4296430500C27081682 @default.
• W4296430500 hasConceptScore W4296430500C2778593092 @default.
• W4296430500 hasConceptScore W4296430500C2779384505 @default.
• W4296430500 hasConceptScore W4296430500C2779399885 @default.
• W4296430500 hasConceptScore W4296430500C2780965833 @default.
• W4296430500 hasConceptScore W4296430500C71924100 @default.
• W4296430500 hasConceptScore W4296430500C90924648 @default.
• W4296430500 hasLocation W42964305001 @default.
• W4296430500 hasOpenAccess W4296430500 @default.
• W4296430500 hasPrimaryLocation W42964305001 @default.
• W4296430500 hasRelatedWork W2008803377 @default.
• W4296430500 hasRelatedWork W2036508081 @default.
• W4296430500 hasRelatedWork W2110351318 @default.
• W4296430500 hasRelatedWork W2158293825 @default.
• W4296430500 hasRelatedWork W2160783920 @default.
• W4296430500 hasRelatedWork W2161349865 @default.
• W4296430500 hasRelatedWork W2358347379 @default.
• W4296430500 hasRelatedWork W2417254063 @default.
• W4296430500 hasRelatedWork W3212190881 @default.
• W4296430500 hasRelatedWork W51976641 @default.
• W4296430500 isParatext "false" @default.
• W4296430500 isRetracted "false" @default.
• W4296430500 workType "article" @default.